Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,774 across all filing types
Latest filing 2018-08-09 Interim / Quarterly Rep…
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Präsentation H1 2018
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Evotec AG, H1 2018 Interim Report' and contains detailed financial performance metrics, segment analysis (EVT Execute and EVT Innovate), and operational highlights for the first half of 2018. It is a comprehensive presentation of financial results and business strategy, fitting the definition of an Interim/Quarterly Report (IR). H1 2018
2018-08-09 English
EVOTEC AG TO REPORT FIRST HALF-YEAR 2018 RESULTS ON 09 AUGUST 2018
Report Publication Announcement Classification · 99% confidence The document is a news release dated August 2, 2018, announcing that EVOTEC AG will report its financial results for the first half of 2018 on August 9, 2018. It provides details for the subsequent conference call and webcast. Since the document is an announcement *about* the upcoming release of financial results (specifically 'first half-year 2018 results') rather than the comprehensive report itself (which would be an 'IR' or '10-K'), it fits the definition of a Report Publication Announcement (RPA). The document length (6068 chars) is moderate, but the content is purely informational regarding the timing of a future report release and conference call details, aligning perfectly with RPA.
2018-08-02 English
Evotec AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly mentions the 'Publication of total number of voting rights' and a 'Conditional capital increase' under Article 41 of the WpHG (German Securities Trading Act). This type of announcement, detailing changes in the total number of shares/voting rights, is a specific regulatory disclosure. It is not a full annual report (10-K), an earnings release (ER), or a general management change (MANG). While it relates to capital structure, the specific focus on the total voting rights count points towards a regulatory filing concerning share structure changes. Given the options, this specific disclosure about voting rights and capital structure changes fits best under 'Capital/Financing Update' (CAP) or potentially 'Regulatory Filings' (RNS) if CAP is too broad. However, since it details a specific capital measure (conditional capital increase) and the resulting total voting rights, CAP is a strong candidate. Alternatively, since it is a formal announcement under German securities law (WpHG) distributed via DGAP, it is a regulatory disclosure. Since there isn't a specific 'Voting Rights Change' code, and it is a formal regulatory notice, RNS (Regulatory Filings) serves as the appropriate general regulatory category for such specific, non-financial-statement disclosures, although CAP is also relevant. Given the structure and content (announcing a specific change in the total number of voting rights due to a capital measure), I will classify it as a Capital/Financing Update (CAP) as it directly addresses a change in the capital structure, which is more specific than the general RNS fallback.
2018-07-31 English
EVOTEC REPAYS 50% OF EUR 140 M ACQUISITION LOAN
Capital/Financing Update Classification · 95% confidence The document is a news release dated July 31, 2018, announcing that Evotec AG repaid 50% of a EUR 140M acquisition loan taken out for the Aptuit acquisition in August 2017. The content focuses on debt repayment, operational cash flow, and financial structure management, rather than a full periodic financial report (like 10-K or IR) or a formal regulatory filing like a Director's Dealing or Major Shareholding notification. Since it discusses financing activities and capital structure changes (repayment of debt facility), it aligns best with the 'Capital/Financing Update' category.
2018-07-31 English
EVOTEC RECEIVES MILESTONE PAYMENT FOR START OF PHASE II TRIAL IN ITS MULTI-TARGET ALLIANCE WITH BAYER
Regulatory Filings Classification · 100% confidence The document is a press release titled 'EVOTEC RECEIVES MILESTONE PAYMENT FOR START OF PHASE II TRIAL IN ITS MULTI-TARGET ALLIANCE WITH BAYER'. It announces a specific corporate event (receiving a milestone payment due to a clinical trial advancing) and includes standard boilerplate text for news dissemination via DGAP. This type of announcement, which details operational progress, partnership milestones, and financial receipts related to R&D, does not fit neatly into the specific financial report categories (10-K, IR, ER) or governance/shareholder categories. It is a general corporate news item. Since it is not a formal regulatory filing like a 10-K or a specific report like an Earnings Release (ER), and it is not announcing the publication of a major report (RPA), the most appropriate general category for significant, non-standard corporate news disseminated via a service like DGAP is 'Regulatory Filings' (RNS) as the fallback for miscellaneous corporate announcements.
2018-07-19 English
EVOTEC CONFIRM CLOSING OF TRANSACTION WITH SANOFI TO ACCELERATE INFECTIOUS DISEASE RESEARCH AND DEVELOPMENT
M&A Activity Classification · 99% confidence The document is a press release titled "EVOTEC CONFIRM CLOSING OF TRANSACTION WITH SANOFI TO ACCELERATE INFECTIOUS DISEASE RESEARCH AND DEVELOPMENT". It announces the successful closing of a strategic transaction involving asset integration and financial commitments. This type of announcement, detailing a significant business event, partnership closing, or corporate development that is not a standard periodic financial report (like 10-K or IR) or a specific insider trade/dividend notice, typically falls under general corporate news or regulatory filings. Since it is a specific announcement about a major business transaction (acquisition/integration), it is best classified as a general Regulatory Filing (RNS) as it doesn't fit the specific categories like CAP (Capital/Financing Update) or TAR (M&A Activity - which usually implies a takeover bid or merger proposal, whereas this is a specific asset integration closing). Given the options, RNS serves as the best general regulatory announcement category for significant, non-standard corporate events not covered elsewhere. The document length (5595 chars) is substantial enough that it is the report itself, not just an announcement of a report (RPA).
2018-07-03 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.